Ramona Coffie, MD
Family Medicine · Radcliff, KYNPI 1235391566
Payments from drug & device makers
Across 244 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$679
- Novo Nordisk$364
- Amgen$354
- GSK$341
- Pfizer$293
- Astellas Pharma US Inc$253
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,803100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $679 |
| Novo Nordisk | 27 | $364 |
| Amgen | 23 | $354 |
| GSK | 23 | $341 |
| Pfizer | 20 | $293 |
| Astellas Pharma US Inc | 13 | $253 |
| Lilly USA, LLC | 15 | $209 |
| Bayer | 8 | $140 |
| Sanofi-aventis U.S. LLC | 8 | $113 |
| Idorsia Pharmaceuticals US Inc | 6 | $100 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $85 |
| AstraZeneca | 5 | $80 |
| Otsuka America Pharmaceutical, Inc. | 4 | $77 |
| Boehringer Ingelheim | 5 | $71 |
| Axsome Therapeutics, Inc. | 3 | $70 |
| Xeris Pharmaceuticals, Inc. | 3 | $62 |
| Sumitomo Pharma America, Inc. | 3 | $57 |
| Johnson & Johnson | 3 | $55 |
| Novartis | 3 | $53 |
| Merck | 2 | $42 |
| Exact Sciences | 2 | $38 |
| Abbott | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 3 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Tris Pharma Inc | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $19 |
| Insulet Corporation | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| Harmony Biosciences LLC | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,803 in reported general payments places this provider in the 80th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $75,059 |
| MounjaroTirzepatide | 26 | $33,949 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $32,004 |
| LinzessLinaclotide | 25 | $29,169 |
| MyrbetriqMirabegron | 36 | $26,649 |
| EliquisApixaban | 24 | $24,980 |
| JanuviaSitagliptin Phosphate | 28 | $22,352 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $17,574 |
| VeozahFezolinetant | 31 | $16,761 |
| TrulicityDulaglutide | 16 | $15,364 |
| Nurtec OdtRimegepant Sulfate | 15 | $14,725 |
| JardianceEmpagliflozin | 15 | $14,164 |
| QuliptaAtogepant | 11 | $13,968 |
| XareltoRivaroxaban | 17 | $13,641 |
| Repatha SureclickEvolocumab | 24 | $13,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $364 | $75,05961 claims |
| Lilly USA, LLCMounjaro, Trulicity | $209 | $49,31342 claims |
| AbbVieLinzess, Qulipta, Synthroid | $679 | $43,90350 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $253 | $43,41067 claims |
| PfizerEliquis, Nurtec Odt, Prempro | $293 | $42,31750 claims |
| GSKTrelegy Ellipta | $341 | $32,00444 claims |
| MerckJanuvia | $42 | $22,35228 claims |
| Boehringer IngelheimJardiance | $71 | $14,16415 claims |
| Johnson & JohnsonXarelto | $55 | $13,64117 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $12 | $10,21518 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $100 | $6,31313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Radcliff
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.